OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Goy on NCCN Guidelines for Lymphomas

May 2nd 2014

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses NCCN guidelines for the treatment of lymphomas.

Dr. Yu on the Association of ALP With Outcomes in Patients With mCRPC

May 1st 2014

Evan Y. Yu, MD, from Seattle Cancer Care Alliance, discusses the association of alkaline phosphatase with outcomes in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.

Dr. Ramanathan on Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer

April 30th 2014

Ramesh K. Ramanathan, MD, describes a phase II study that analyzed gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.

Dr. Tripathy on the Treatment of Patients With MBC

April 29th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses advances in the treatment of metastatic breast cancer.

Dr. Dreicer on Trial Endpoints in Prostate Cancer

April 29th 2014

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

Dr. Halmos on the Impact of EGFR Inhibitors on the Treatment of Lung Cancer

April 28th 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the impact of EGFR inhibitors on the treatment of lung cancer.

Dr. Seymour Discusses the Results of the PRIMA Study

April 28th 2014

John F. Seymour, MBBS, FRACP, PhD, from the Department of Hematology at the Peter MacCallum Cancer Centre in East Melbourne, Australia, discusses the results of the PRIMA study, which evaluated the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy in patients with advanced follicular lymphoma.

Dr. Hsieh Discusses New Treatments for Kidney Cancer

April 25th 2014

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, gives an overview of emerging treatments for patients with kidney cancer.

Dr. Petrylak on Imaging Approaches in Prostate Cancer

April 25th 2014

Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, describes imaging approaches in prostate cancer

Dr. Brentjens on the Potential Application of CAR-Modified T Cell Technology

April 24th 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential application of CAR-modified T cell technology.

Dr. Schneiderman on Rationing Medical Care

April 24th 2014

Lawrence J. Schneiderman, MD, professor emeritus, Medicine/Family & Preventive Medicine, University of California, San Diego (UCSD), discusses preparing doctors for the fact that medical care will have to be rationed in the future.

Dr. Kunz on Identifying Gastric Cancer Subtypes

April 23rd 2014

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses the effort to identify molecular subtypes of gastric cancer.

Dr. Pal on Sequencing Abiraterone and Enzalutamide in mCRPC

April 23rd 2014

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses the results of a retrospective analysis of the effect of prior abiraterone use on the activity level of enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC).

Ellen T. Matloff on Changes to the Field of Genetic Testing

April 22nd 2014

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, gives an overview of the recent changes to the field of genetic testing.

Dr. Crawford Discusses Prostate Cancer Biopsies

April 22nd 2014

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses prostate cancer biopsies.

Dr. Komrokji on Pacritinib for the Treatment of Myelofibrosis

April 21st 2014

Rami S. Komrokji, MD, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses an analysis of pacritinib for the treatment of myelofibrosis.

Dr. Richter on Novel Oral Anticoagulants

April 21st 2014

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses the use of novel oral anticoagulants for use in patients with hematologic malignancies.

Dr. Salerno on Access to Care for Breast Cancer Patients

April 17th 2014

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, discusses access to care for patients with breast cancer.

Dr. Penson on Advantages/ Disadvantages of Large Urologic Practices

April 17th 2014

David F. Penson, MD, MPH, director, Center for Surgical Quality and Outcomes Research Professor of Urologic Surgery, Paul V. Hamilton, M.D. and Virginia E. Howd Chair in Urologic Oncology, professor of medicine, Vanderbilt University Medical Center, discusses some of the advantages and disadvantages of a large urologic practice.

Dr. Sartor on Distinguishing Between Symptomatic and Asymptomatic Patients

April 16th 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the distinction between symptomatic and asymptomatic patients with bone metastases from prostate cancer.